In vitro characterization and in vivo comparison of the pulmonary outcomes of Poractant alfa and Calsurf in ventilated preterm rabbits.
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Guo, XiaojingLuo, Siwei
Amidani, Davide
Rivetti, Claudio
Pieraccini, Giuseppe
Pioselli, Barbara
Catinella, Silvia
Murgia, Xabi
Salomone, Fabrizio
Xu, Yaling
Dong, Ying
Sun, Bo
Issue Date
2020-03-13
Metadata
Show full item recordAbstract
Poractant alfa and Calsurf are two natural surfactants widely used in China for the treatment of neonatal respiratory distress syndrome, which are extracted from porcine and calf lungs, respectively. The purpose of this experimental study was to compare their in vitro characteristics and in vivo effects in the improvement of pulmonary function and protection of lung injury. The biophysical properties, ultrastructure, and lipid composition of both surfactant preparations were respectively analysed in vitro by means of Langmuir-Blodgett trough (LBT), atomic force microscopy (AFM), and liquid-chromatography mass-spectrometry (LC-MS). Then, as core pharmacological activity, both head-to-head (100 and 200 mg/kg for both surfactants) and licensed dose comparisons (70 mg/kg Calsurf vs. 200 mg/kg Poractant alfa) between the two surfactants were conducted as prophylaxis in preterm rabbits with primary surfactant deficiency, assessing survival time and rate and dynamic compliance of the respiratory system (Cdyn). Intrapulmonary surfactant pools, morphometric volume density as alveolar expansion (Vv), and lung injury scores were determined post mortem. AFM and LC-MS analysis revealed qualitative differences in the ultrastructure as well as in the lipid composition of both preparations. Calsurf showed a longer plateau region of the LBT isotherm and lower film compressibility. In vivo, both surfactant preparations improved Cdyn at any dose, although maximum benefits in terms of Vv and intrapulmonary surfactant pools were seen with the 200 mg/kg dose in both surfactants. The group of animals treated with 200 mg/kg of Poractant alfa showed a prolonged survival time and rate compared to untreated but ventilated controls, and significantly ameliorated lung injury compared to Calsurf at any dose, including 200 mg/kg. The overall outcomes suggest the pulmonary effects to be dose dependent for both preparations. The group of animals treated with 200 mg/kg of Poractant alfa showed a significant reduction of mortality. Compared to Calsurf, Poractant alfa exerted better effects if licensed doses were compared, which requires further investigation.Citation
PLoS One. 2020 Mar 13;15(3):e0230229. doi: 10.1371/journal.pone.0230229. eCollection 2020.Affiliation
HIPS, Helmholtz-Institut für Pharmazeutische Forschung Saarland, Universitätscampus E8.1 66123 Saarbrücken, Germany.Publisher
PLOSJournal
PloS onePubMed ID
32168331Type
ArticleLanguage
enEISSN
1932-6203ae974a485f413a2113503eed53cd6c53
10.1371/journal.pone.0230229
Scopus Count
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 4.0 International
Related articles
- In vitro and in vivo comparison between poractant alfa and the new generation synthetic surfactant CHF5633.
- Authors: Ricci F, Murgia X, Razzetti R, Pelizzi N, Salomone F
- Issue date: 2017 Feb
- Comparison of poractant alfa and lyophilized lucinactant in a preterm lamb model of acute respiratory distress.
- Authors: Mazela J, Merritt A, Terry MH, Gregory TJ, Blood AB
- Issue date: 2012 Jul
- Poractant alfa and beractant treatment of very premature infants with respiratory distress syndrome.
- Authors: Fujii AM, Patel SM, Allen R, Doros G, Guo CY, Testa S
- Issue date: 2010 Oct
- Patent ductus arteriosus hemodynamics in very premature infants treated with poractant alfa or beractant for respiratory distress syndrome.
- Authors: Fujii A, Allen R, Doros G, O'Brien S
- Issue date: 2010 Oct
- A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome.
- Authors: Sinha SK, Lacaze-Masmonteil T, Valls i Soler A, Wiswell TE, Gadzinowski J, Hajdu J, Bernstein G, Sanchez-Luna M, Segal R, Schaber CJ, Massaro J, d'Agostino R, Surfaxin Therapy Against Respiratory Distress Syndrome Collaborative Group
- Issue date: 2005 Apr